Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000339502 | SCV000331714 | other | not provided | 2015-07-10 | criteria provided, single submitter | clinical testing | |
Medical Genetics Summaries | RCV000787930 | SCV000926949 | drug response | Flurbiprofen response | 2019-02-11 | criteria provided, single submitter | curation | The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance. |
Medical Genetics Summaries | RCV000788094 | SCV000927092 | drug response | Lesinurad response | 2019-02-11 | criteria provided, single submitter | curation | Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects. |
Medical Genetics Summaries | RCV000788100 | SCV000927098 | drug response | Piroxicam response | 2019-02-11 | criteria provided, single submitter | curation | Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals. |
OMIM | RCV000008916 | SCV000029126 | drug response | Tolbutamide response | 2010-12-30 | no assertion criteria provided | literature only | |
OMIM | RCV000008917 | SCV000029127 | drug response | Warfarin response | 2012-06-15 | no assertion criteria provided | literature only | |
OMIM | RCV000008918 | SCV000029128 | drug response | Phenytoin response | 2012-06-15 | no assertion criteria provided | literature only | |
OMIM | RCV000008919 | SCV000029129 | drug response | Glipizide response | 2012-06-15 | no assertion criteria provided | literature only | |
Pharmacogenomics Lab, |
RCV000008917 | SCV000889937 | drug response | Warfarin response | 2010-08-31 | no assertion criteria provided | research | |
Equipe Genetique des Anomalies du Developpement, |
RCV000008918 | SCV001441534 | drug response | Phenytoin response | 2020-09-24 | no assertion criteria provided | case-control | May cause toxicity/ADR and poor metabolism/PK |